Operational Issues in Clinical Trial Disclosure of Global Trials

被引:0
|
作者
Shown M. Pelletier
Maureen A. Strange
Barbara J. Godlew
机构
[1] Business Operations,Clinical Trial Transparency, Global Development Medical Affairs
[2] Bristol-Myers Squibb,Medical Quality, Clinical Trial Registry, Global Medical Quality
[3] Eli Lilly and Company,undefined
[4] The FAIRE Company,undefined
[5] LLC,undefined
关键词
Maine; Clinical trial disclosure; FDAAA; Operations; Process;
D O I
暂无
中图分类号
学科分类号
摘要
In hospitals and clinics around the world, ordinary people place their health and their very lives in the hands of researchers who test new experimental drugs for safety and effectiveness. The public and legislators worldwide have expressed increasing interest in understanding how clinical trials are conducted and the results of those trials. The list of stakeholders has grown substantially in recent years to include medical and scientific academia, government agencies, regulatory authorities, and advocacy groups. Quite logically, stakeholders’ interests have shifted slightly from the registration of clinical trial protocol information to the posting of clinical trial results upon trial completion. Protocol registration and results reporting requirements are staggering, diverse, and complex. This article provides a look at industry experience with the operational challenges of clinical trial registries and results databases that the pharmaceutical, medical device, and biotechnology industry, and academia face when providing clinical trial information.
引用
收藏
页码:253 / 264
页数:11
相关论文
共 50 条
  • [11] Public disclosure of clinical trials in children
    Clavenna, A
    Pandolfini, C
    Bonati, M
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2002, 63 (10): : 707 - 716
  • [12] THE REWARDS OF CLINICAL-TRIALS - DISCLOSURE
    LIPPER, S
    HAMMETT, E
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1986, 256 (02): : 216 - 216
  • [13] Calls for full disclosure of clinical trials
    Simon Frantz
    Nature Reviews Drug Discovery, 2004, 3 (8) : 635 - 636
  • [14] The future of the global clinical trial ecosystem: a vision from the first WHO Global Clinical Trials Forum
    Moorthy, Vasee
    Abubakar, Ibrahim
    Qadri, Firdausi
    Ogutu, Bernhards
    Zhang, Wei
    Reeder, John
    Farrar, Jeremy
    LANCET, 2024, 403 (10422): : 124 - 126
  • [15] Operational Strategies for Clinical Trials in Africa
    Graef, Katy M.
    Okoye, Ifeoma
    Oti, Naomi O. Ohene
    Dent, Jennifer
    Odedina, Folakemi T.
    JCO GLOBAL ONCOLOGY, 2020, 6 : 973 - 982
  • [16] Clinical trial design issues: At least 10 things you should look for in clinical trials
    Glasser, Stephen P.
    Howard, George
    JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (10): : 1106 - 1115
  • [17] Statistical issues in clinical trials
    Black, D.
    CALCIFIED TISSUE INTERNATIONAL, 2008, 82 : S15 - S15
  • [18] Issues in the design of clinical trials
    Feldman, Martha A.
    Medical Device and Diagnostic Industry, 1993, 15 (11): : 96 - 102
  • [19] Multiplicity issues in clinical trials
    Benda, Norbert
    Bender, Ralf
    BIOMETRICAL JOURNAL, 2011, 53 (06) : 873 - 874
  • [20] Issues in the registration of clinical trials
    Zarin, Deborah A.
    Ide, Nicholas C.
    Tse, Tony
    Harlan, William R.
    West, Joyce C.
    Lindberg, Donald A. B.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (19): : 2112 - 2120